Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dishman Pharmaceuticals and Chemicals, a manufacturer of active pharmaceutical ingredients (API), intermediates, quaternary compounds, and crown ethers, has said that its Bavla facilities are approved by Therapeutic Goods Administration (TGA), Department of Health and Ageing of government of Australia, for the production of all APIs, reported MyIris.
Subscribe to our email newsletter
Dishman Pharma, through synthetic chemistry research, has developed manufacturing processes for various intermediates, APIs, quarternary ammonium compounds (QUATS) and specialty chemicals.
Dishman is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and manufacturing services. The products and services offered span customers’ needs from chemical development to commercial manufacture and supply of active pharmaceutical ingredients. Dishman has customer base in Europe, China and India
Recently, Dishman’s Ahmedabad-based EOU facility had received the US FDA nod for API production.
The Dishman group consists of five different business units: Specialty Chemicals located in India, China; Carbogen Amics in Switzerland, UK, India; Contract Research and Manufacturing (CRAMS) in India, China; Vitamins & Chemicals in Netherlands, India; and Disinfectants in India, Australasia, Saudi Arabia.